Analysts expect Nautilus Biotechnology, Inc. to report revenue of 255,222.19 for Q4 26, against a range of 246,981.32 to 263,463.06. The most recent reported quarter, Q3 26, came in at 234,000.00, a 16.4% beat against the 201,078.28 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 190,000.00 | 234,000.00 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 209,856.75 | 263,463.06 | 376,375.33 | 631,133.84 | 1.87 M | 1.37 M | 3.93 M | 4.20 M | 5.76 M | |||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 192,299.81 | 246,981.32 | 353,329.79 | 567,973.28 | 1.66 M | 1.28 M | 3.70 M | 3.61 M | 5.25 M | |||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 201,078.28 | 255,222.19 | 364,852.56 | 599,553.56 | 1.77 M | 1.33 M | 3.81 M | 3.90 M | 5.50 M |
Analysts expect Nautilus Biotechnology, Inc. to report earnings per share of -0.15 for Q4 26, against a range of -0.16 to -0.14. The most recent reported quarter, Q3 26, came in at -0.12, a 20.0% beat against the -0.15 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.14 | -0.13 | -0.12 | -0.11 | -0.11 | -0.12 | -0.11 | -0.12 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | -0.15 | -0.13 | -0.15 | -0.15 | -0.14 | -0.12 | -0.12 | -0.14 | -0.14 | -0.11 | -0.12 | -0.12 | -0.12 | -0.12 | -0.10 | -0.11 | |||||||||
| Low Estimate | -0.17 | -0.15 | -0.17 | -0.17 | -0.16 | -0.14 | -0.14 | -0.16 | -0.16 | -0.13 | -0.14 | -0.14 | -0.14 | -0.14 | -0.12 | -0.13 | |||||||||
| Consensus Estimate | -0.16 | -0.14 | -0.16 | -0.16 | -0.15 | -0.13 | -0.13 | -0.15 | -0.15 | -0.12 | -0.13 | -0.13 | -0.13 | -0.13 | -0.11 | -0.12 |
Pull Wall Street consensus for Nautilus Biotechnology, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=NAUT&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "NAUT", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=NAUT&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();